Ainos Inc (AIMD) News & EventsAIMDAinos Inc

Ainos Completes VELDONA Data Delivery, Triggers $600,000 Initial Payment

Ainos has completed the required data delivery and technology transfer under its VELDONA license agreement, triggering a $600,000 initial license payment. The licensing partner confirmed completion in writing on September 29. Payment is due within 15 business days under the agreement. The delivery includes clinical and regulatory materials for Sjogren's disease and thrombocytopenia, providing a foundation for the partner's continued development work in autoimmune and hematologic diseases. The initial payment is part of the previously announced potential $10M licensing framework, which also includes conditional payments tied to the first sublicense and licenses for 15 additional indications. Ainos is separately entitled to 25% of net sublicensing revenue, as defined in the agreement.

Ainos Completes Delivery of 1,400 AI Nose Systems to ASE

Ainos has completed delivery of all 1,400 AI Nose systems to ASE Technology Holding under the announced $2.1M, three-year agreement. The completed delivery marks a major commercial milestone for Ainos' Chemical Intelligence platform in advanced back-end semiconductor manufacturing. Management expects the delivery to contribute to revenue beginning in the third-quarter 2026 revenue, advancing the Company's previously communicated second-half commercialization outlook. ASE's experience deploying the first-phase systems across different locations, primarily in advanced packaging processes, has helped identify the need for broader coverage. Ainos has begun discussion for a larger scale, second-phase deployment based on the companies' existing memorandum of understanding. A separate agreement is currently under negotiation to cover that phase.

Ainos VELDONA License Agreement Initial Fee of $600,000

Ainos detailed the financial and strategic benefits of the VELDONA License Agreement announced on September 24. Ainos expects to complete the agreed contractual delivery shortly, with an initial license fee of $600,000 payable within 15 business days after the applicable payment conditions are satisfied. This payment does not depend on completion of future clinical trials or receipt of marketing approval. The pharmaceutical development partner identified in the September 24 announcement will fund and execute the clinical and regulatory activities assigned to it for the two initial globally licensed indications, Sjogren's disease and thrombocytopenia. This structure reduces Ainos' need to independently finance subsequent development, expand specialist teams and devote additional management resources to pharmaceutical execution, supporting the Company's priority investment in Chemical Intelligence. Ainos is also entitled to 25% of applicable net sublicensing revenue. Qualifying transactions may generate upfront payments, option fees and development or regulatory milestones during clinical development, creating opportunities for payments to Ainos before a product reaches the market. The Agreement provides distinct sources of potential consideration: Initial license fee: $600,000 payable under the contractual delivery and payment provisions. Sublicensing participation: 25% of applicable net sublicensing revenue, which may include upfront payments, option fees, milestones, royalties and other consideration covered by the Agreement. First-sublicense fee: A separate, one-time fee payable within 30 days after the first third-party sublicense takes effect, without reducing or offsetting Ainos' applicable revenue share. Additional indication licenses: A pathway for 15 additional VELDONA indications, subject to applicable contractual rights, separate definitive agreements and payment. Product supply: Opportunities under separately negotiated agreements and accepted purchase orders. The potential $10M framework comprises the initial license fee, conditional additional-indication consideration and the first-sublicense fee. Partner-funded development expenditures, applicable sublicensing revenue participation and potential product supply revenue are additional to that framework. Where additional indication licenses carry forward the 25% net sublicensing participation, that share would be additional to the corresponding license fees. Accordingly, $10M is not a ceiling on Ainos' total economic participation. Further value will depend on completed licenses, qualifying sublicensing transactions and supply arrangements. Neither party is obligated to complete all 15 additional licenses, and the framework represents neither guaranteed revenue nor a platform valuation. The 25% share applies to the defined net sublicensing revenue base, subject to permitted deductions and other applicable terms. Payments depend on qualifying transactions, receipt of consideration and contractual payment provisions; clinical activity alone does not trigger a payment. License fees, the first-sublicense fee and separate supply payments are independent of that percentage calculation. Ainos may also negotiate direct licenses for available indications with other third parties, subject to the licensee's applicable contractual priority rights. Consideration contemplated under this Agreement does not set a ceiling on those separately negotiated transactions.